Preliminary and unaudited figures indicate that ODI achieved revenues of approximately SEK 11 million during the second quarter 2025/2026. This corresponds to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial increase compared to the corresponding quarter of the previous fiscal year, when revenues amounted to SEK 0.

All figures are preliminary and unaudited. The full results for the period will be published in the interim report scheduled for February 26, 2026. Based on the current revenue level, ODI expects to report a positive net result for the second quarter.

The improved performance is primarily driven by increased order volumes, reflecting more stable operational conditions and improved commercial execution compared to earlier periods.

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com  

This disclosure contains information that ODI Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-12-2025 15:30 CET

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.